 |
TREATMENTS IN THE PIPELINE: 150 headlines |
|
|||||
My Educational Video on MS and MS Trials| Visitors Since 03/2006 |
||||||||||||||||||||||||||||||||||||||
| Our 670 MySpace Friends The New Face of MS |
||||||||||||||||||||||||||||||||||||||
 |
||||||||||||||||||||||||||||||||||||||
| ||||||||||||||||||||||||||||||||||||||
| ||||||||||||||||||||||||||||||||||||||
| ||||||||||||||||||||||||||||||||||||||
| ||||||||||||||||||||||||||||||||||||||
| ||||||||||||||||||||||||||||||||||||||
 Click to view 1280 MS Walk photos! | ||||||||||||||||||||||||||||||||||||||
| "Join a trial at Barrow & receive all medication & study based procedures at no charge!" | ||||||||||||||||||||||||||||||||||||||
Stan Swartz, CEO, The MD Health Channel "WE PRODUCED THE FOLLOWING 9 VIDEOS FOR YOU!" Simply click the "video" buttons below: . |
||||||||||||||||||||||||||||||||||||||
|
||||||||||||||||||||||||||||||||||||||
|
||||||||||||||||||||||||||||||||||||||
|
||||||||||||||||||||||||||||||||||||||
|
||||||||||||||||||||||||||||||||||||||
|
||||||||||||||||||||||||||||||||||||||
|
||||||||||||||||||||||||||||||||||||||
| Previious Posts | ||||||||||||||||||||||||||||||||||||||
|
||||||||||||||||||||||||||||||||||||||
| MS NEWS ARCHIVES: by week | ||||||||||||||||||||||||||||||||||||||
| June 2006 | ||||||||||||||||||||||||||||||||||||||
| July 2006 | ||||||||||||||||||||||||||||||||||||||
| August 2006 | ||||||||||||||||||||||||||||||||||||||
| September 2006 | ||||||||||||||||||||||||||||||||||||||
| October 2006 | ||||||||||||||||||||||||||||||||||||||
| November 2006 | ||||||||||||||||||||||||||||||||||||||
Wednesday
Improved walking speed and leg strength in people with MS taking Fampridine-SR [click for more at UK MS Society
Acorda Therapeutics reported positive results following a 14 week phase III clinical trial with a slow release tablet form of 4-aminopyridine (drug name: Fampridine-SR). The drug is thought to improve the conduction of nerve impulses, even if the nerve fibres' insulating coat of myelin has been damaged as a result of MS.
The company reported that 35% of people responded to the treatment, showing an average increase of 25% in their walking speed compared to those on placebo. Another positive outcome was increased leg strength in those on active treatment. People that responded to the drug, also reported feeling "less disabled" in daily activities requiring mobility.
Dr. Lee Dunster, Head of Research at the MS Society said: "We welcome the positive results of an experimental symptomatic therapy that could improve mobility and quality of life in people with different types of MS. We are waiting to see that the new slow-release formulation fulfils safety requirements."
Acorda Therapeutics reported positive results following a 14 week phase III clinical trial with a slow release tablet form of 4-aminopyridine (drug name: Fampridine-SR). The drug is thought to improve the conduction of nerve impulses, even if the nerve fibres' insulating coat of myelin has been damaged as a result of MS.
The company reported that 35% of people responded to the treatment, showing an average increase of 25% in their walking speed compared to those on placebo. Another positive outcome was increased leg strength in those on active treatment. People that responded to the drug, also reported feeling "less disabled" in daily activities requiring mobility.
Dr. Lee Dunster, Head of Research at the MS Society said: "We welcome the positive results of an experimental symptomatic therapy that could improve mobility and quality of life in people with different types of MS. We are waiting to see that the new slow-release formulation fulfils safety requirements."